Michael S Gordon MD
Genitourinary Oncology, Gynecologic Cancer, Hematologic Oncology, Melanoma
Chief Medical Officer at HonorHealth Research Institute Medical Director, Oncology Clinical Trials at HonorHealth Research Institute
Join to View Full Profile
10510 N 92nd Street Suite 200Scottsdale, AZ 85258
Phone+1 480-323-1350
Dr. Gordon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
University of ChicagoResidency, Internal Medicine, 1985 - 1988
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1985
Sophie Davis School for Biomedical Education at CCNYBS, Biomedical Science, 1979 - 1983
Certifications & Licensure
AZ State Medical License 2000 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema
- Safety and Efficacy Study of Glufosfamide in Ovarian Cancer Start of enrollment: 2007 Jan 01
- Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors Start of enrollment: 2008 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer.Oladapo O Yeku, Minal Barve, Winston W Tan, Judy Wang, Amita Patnaik
Journal for Immunotherapy of Cancer. 2025-03-13 - Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastat...Breelyn A Wilky, Gary K Schwartz, Michael S Gordon, Anthony B El-Khoueiry, Andrea J Bullock
Journal of Clinical Oncology. 2025-01-27 - 17 citationsBotensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial.Andrea J Bullock, Benjamin L Schlechter, Marwan G Fakih, Apostolia M Tsimberidou, Joseph E Grossman
Nature Medicine. 2024-09-01
Journal Articles
- Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung CarcinomaBeth A Hellerstedt, Nicholas J Vogelzang, Harriet M Kluger, Christopher A Yasenchak, Michael S Gordon, Primo Lara, Clinical Lung Cancer
- E6201, an Intravenous MEK1 Inhibitor, Achieves an Exceptional Response in BRAF V600E-Mutated Metastatic Malignant Melanoma with Brain MetastasesMitesh J Borad, Raoul Tibes, Michael S Gordon, Ronald L Korn, Investigational New Drugs
Authored Content
- Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung CarcinomaOctober 2018
Press Mentions
HonorHealth Researchers Experimenting with Olives in Anticancer DrugMarch 4th, 2025
TGen Partners with a Phoenix-Area Hospital System to Test COVID-19 TreatmentMay 5th, 2020
Advances in Cancer TreatmentSeptember 29th, 2017- Join now to see all
Professional Memberships
- Member
- Member
Industry Relationships
- co-Founder, Caremission
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
